HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.

Abstract
Tumor recurrence after curative resection remains a major problem in patients with locally advanced colorectal cancer treated with adjuvant chemotherapy. Genetic single-nucleotide polymorphisms (SNP) may serve as useful molecular markers to predict clinical outcomes in these patients and identify targets for future drug development. Recent in vitro and in vivo studies have demonstrated that the plastin genes PLS3 and LCP1 are overexpressed in colon cancer cells and play an important role in tumor cell invasion, adhesion, and migration. Hence, we hypothesized that functional genetic variations of plastin may have direct effects on the progression and prognosis of locally advanced colorectal cancer. We tested whether functional tagging polymorphisms of PLS3 and LCP1 predict time to tumor recurrence (TTR) in 732 patients (training set, 234; validation set, 498) with stage II/III colorectal cancer. The PLS3 rs11342 and LCP1 rs4941543 polymorphisms were associated with a significantly increased risk for recurrence in the training set. PLS3 rs6643869 showed a consistent association with TTR in the training and validation set, when stratified by gender and tumor location. Female patients with the PLS3 rs6643869 AA genotype had the shortest median TTR compared with those with any G allele in the training set [1.7 vs. 9.4 years; HR, 2.84; 95% confidence interval (CI), 1.32-6.1; P = 0.005] and validation set (3.3 vs. 13.7 years; HR, 2.07; 95% CI, 1.09-3.91; P = 0.021). Our findings suggest that several SNPs of the PLS3 and LCP1 genes could serve as gender- and/or stage-specific molecular predictors of tumor recurrence in stage II/III patients with colorectal cancer as well as potential therapeutic targets.
AuthorsYan Ning, Armin Gerger, Wu Zhang, Diana L Hanna, Dongyun Yang, Thomas Winder, Takeru Wakatsuki, Melissa J Labonte, Sebastian Stintzing, Nico Volz, Yu Sunakawa, Stefan Stremitzer, Rita El-Khoueiry, Heinz-Josef Lenz
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 13 Issue 2 Pg. 528-39 (Feb 2014) ISSN: 1538-8514 [Electronic] United States
PMID24170770 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • LCP1 protein, human
  • Membrane Glycoproteins
  • Microfilament Proteins
  • plastin
  • Fluorouracil
Topics
  • Aged
  • Alleles
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Chemotherapy, Adjuvant
  • Colonic Neoplasms (drug therapy, genetics, pathology)
  • Disease-Free Survival
  • Female
  • Fluorouracil (administration & dosage)
  • Gene Frequency
  • Genotype
  • Humans
  • Male
  • Membrane Glycoproteins (genetics)
  • Microfilament Proteins (genetics)
  • Middle Aged
  • Multivariate Analysis
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Polymorphism, Single Nucleotide
  • Prognosis
  • Sex Factors
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: